Cargando…

Small-Molecule Compounds Boost CAR-T Cell Therapy in Hematological Malignancies

Although chimeric antigen receptor T cell immunotherapy has been successfully applied in patients with hematological malignancies, several obstacles still need to be overcome, such as high relapse rates and side effects. Overcoming the limitations of CAR-T cell therapy and boosting the efficacy of C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Xinping, Jin, Xin, Zhang, Xiaomei, Utsav, Paudel, Zhang, Yi, Guo, Ruiting, Lu, Wenyi, Zhao, Mingfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Leukemia (PH Wiernik, Section Editor)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992085/ https://www.ncbi.nlm.nih.gov/pubmed/36701037 http://dx.doi.org/10.1007/s11864-023-01049-4

Ejemplares similares

When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
por: Laneuville, Pierre
Publicado: (2018)

Treatment of Relapsed Acute Myeloid Leukemia
por: Thol, Felicitas, et al.
Publicado: (2020)

In Utero Development and Immunosurveillance of B Cell Acute Lymphoblastic Leukemia
por: Rüchel, Nadine, et al.
Publicado: (2022)

Central Nervous System Prophylaxis and Treatment in Acute Leukemias
por: Wu, Susan Y., et al.
Publicado: (2022)

Can Immune Therapy Cure Acute Myeloid Leukemia?
por: Gale, Robert Peter
Publicado: (2023)

Novel Approaches for the Treatment of Patients with Richter’s Syndrome
por: Iannello, Andrea, et al.
Publicado: (2022)

How the COVID-19 Pandemic Reshaped the Management of Leukemia and Affected Patient Outcomes
por: Sharafeldin, Noha, et al.
Publicado: (2022)

Obesity and the Risk for a Hematological Malignancy: Leukemia, Lymphoma, or Myeloma
por: Lichtman, Marshall A.
Publicado: (2010)

Antibiotic Management of Patients with Hematologic Malignancies: From Prophylaxis to Unusual Infections
por: Moreno-Sanchez, Francisco, et al.
Publicado: (2022)

AML-355: Incidence and Severity of COVID-19 among Inpatients with Hematologic Malignancies
por: Wozniaki, Natalia, et al.
Publicado: (2021)

CLL-393 Outcomes of COVID-19 Infections in Patients With Hematological Malignancies in Republic of North Macedonia
por: Cvetanoski, Milche, et al.
Publicado: (2022)

Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase
por: Linga, Vijay Gandhi, et al.
Publicado: (2014)

Frequency of 11q23/MLL gene rearrangement in Egyptian childhood acute myeloblastic leukemia: Biologic and clinical significance
por: Hagag, Adel Abdelhaleim, et al.
Publicado: (2014)

A rare case of appendicular skeleton localization in a patient with chronic lymphocytic leukemia successfully treated with salvage radiation therapy
por: Tuscano, Carmelo, et al.
Publicado: (2017)

Bicistronic CAR-T cells targeting CD123 and CLL1 for AML to reduce the risk of antigen escape
por: Xie, Danni, et al.
Publicado: (2023)

COVID-19 Infection in Vaccinated Adult Patients with Hematological Malignancies. Preliminary Results from Epicovideha (Epidemiology of COVID-19 infection in patients with hematological malignancies: A European Haematology Association Survey)
por: Marchesi, Francesco, et al.
Publicado: (2021)

Low-dose administration of prednisone has a good effect on the treatment of prolonged hematologic toxicity post-CD19 CAR-T cell therapy
por: Wang, Jiaxi, et al.
Publicado: (2023)

T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies
por: Tang, Lu, et al.
Publicado: (2021)

A Comparative Outcome Analysis of COVID-19 and Influenza Infection in Patients with Hematological Malignancies
por: Ghandili, Susanne, et al.
Publicado: (2021)

CAR T-Cell Therapy in Hematological Malignancies
por: Haslauer, Theresa, et al.
Publicado: (2021)

The journey of CAR-T therapy in hematological malignancies
por: Lu, Junru, et al.
Publicado: (2022)

Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting
por: Guo, Ruiting, et al.
Publicado: (2022)

Challenges and optimal strategies of CAR T therapy for hematological malignancies
por: Zhang, Yajing, et al.
Publicado: (2023)

Erratum to: CAR T Cell Therapy for Hematological Malignancies
por: Yang, Xin, et al.
Publicado: (2021)

The Transferrin Receptor-Directed CAR for the Therapy of Hematologic Malignancies
por: Guo, Zilong, et al.
Publicado: (2021)

CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
por: Zhang, Xiaomin, et al.
Publicado: (2022)

Targeted CD7 CAR T-cells for treatment of T-Lymphocyte leukemia and lymphoma and acute myeloid leukemia: recent advances
por: Liu, Jile, et al.
Publicado: (2023)

The application of CAR-T cell therapy in hematological malignancies: advantages and challenges
por: Zhao, Zijun, et al.
Publicado: (2018)

COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)
por: Marchesi, Francesco, et al.
Publicado: (2022)

T cell senescence and CAR-T cell exhaustion in hematological malignancies
por: Kasakovski, Dimitri, et al.
Publicado: (2018)

Gene Modified CAR-T Cellular Therapy for Hematologic Malignancies
por: Lin, Wen-Ying, et al.
Publicado: (2020)

Current Progress in CAR-T Cell Therapy for Hematological Malignancies
por: Han, Donglei, et al.
Publicado: (2021)

Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies
por: Jacoby, Elad
Publicado: (2019)

The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy
por: Arruga, Francesca, et al.
Publicado: (2023)

Metagenomic Next-Generation Sequencing for Diagnostically Challenging Mucormycosis in Patients with Hematological Malignancies
por: Zhang, Meng, et al.
Publicado: (2022)

CAR T-Cell Therapy: On the Verge of Breakthrough in Many Hematologic Malignancies
por: Stadtmauer, Edward, et al.
Publicado: (2017)

Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
por: Wang, Hao, et al.
Publicado: (2019)

CAR-NK cell therapeutics for hematologic malignancies: hope is on the horizon
por: Xu, Kai-lin, et al.
Publicado: (2019)

CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies
por: Huang, Jiawen, et al.
Publicado: (2022)

Recent Prospective in CAR T-Based Therapy for Solid and Hematological Malignancies
por: Marei, Hany E., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pvt5hdoea4noitcov9s2pmtnm6